Trial reportThe British journal of ophthalmology2007
3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children.
Trial report in The British journal of ophthalmology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Pooled it
- Bacterial conjunctivitis.BMJ clinical evidence · 2012Pooled it
- Bacterial conjunctivitis.BMJ clinical evidence · 2010Pooled it
- Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.Drugs in R&D · 2017Trial
- Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis.The British journal of ophthalmology · 2014Trial
- Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis.Ophthalmology and therapy · 2021Review
- Efficacy of azithromycin 1% and 1.5% ophthalmic solutions compared to tobramycin 0.3% eye drops: A systematic review and meta-analysis.SAGE open medicine · 2020Review
- Long-acting liposomal corneal anesthetics.Biomaterials · 2018Article
- The Effect of Intravitreal Azithromycin on the Albino Newborn Rabbit Retina.The open ophthalmology journal · 2016Article
- In vitro evaluation of polyethylene glycol based microparticles containing azithromycin.Drug delivery and translational research · 2014Article
- Efficacy of azithromycin 1.5% eye drops in childhood ocular rosacea with phlyctenular blepharokeratoconjunctivitis.Journal of ophthalmic inflammation and infection · 2013Article
- Azithromycin reduces inflammation in a rat model of acute conjunctivitis.Molecular vision · 2013Article
- Azithromycin: assessment of intrinsic cytotoxic effects on corneal epithelial cell cultures.Clinical ophthalmology (Auckland, N.Z.) · 2013Article
- Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis.Drugs · 2012Review
- Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection.Clinical ophthalmology (Auckland, N.Z.) · 2012Article
- A European perspective on topical ophthalmic antibiotics: current and evolving options.Ophthalmology and eye diseases · 2011Article
- Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite) solution in the treatment of ocular infections.Clinical ophthalmology (Auckland, N.Z.) · 2011Article
- Bacterial conjunctivitis.Clinical ophthalmology (Auckland, N.Z.) · 2010Article
- Conjunctivitis: A Systematic Review.Journal of ophthalmic & vision researchReview
- Principles of Ocular Pharmacology.Handbook of experimental pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo compare the efficacy and safety of Azyter, azithromycin 1.5% eye drops, for 3 days with tobramycin 0.3% for 7 days to treat purulent bacterial conjunctivitis.
methodsThis was a multicentre, randomised, investigator-masked study including 1043 children and adults with purulent bacterial conjunctivitis. Patients received either azithromycin 1.5% twice-daily for 3 days or tobramycin 0.3%, 1 drop every two hours for 2 days, then four times daily for 5 days. Clinical signs were evaluated and cultures obtained at D0, D3 and D9 (where D refers to "day"). Primary variable was the clinical cure at the Test-of-Cure (TOC)-visit (D9+/-1), for patients with D0-positive cultures. The cure was defined as: bulbar conjunctival injection and discharge scores of 0.
resultsAmong 471 patients with D0-positivity in the per protocol set, 87.8% of the azithromycin 1.5% group and 89.4% of the tobramycin group were clinically cured at the TOC-visit. Azithromycin was non-inferior to tobramycin for clinical and bacteriological cure. Clinical cure was significantly higher with azithromycin 1.5% at D3. The safety profile of azithromycin was satisfactory with a good patient and investigator's acceptability.
conclusionsAzithromycin 1.5% for 3 days was as effective and as safe as tobramycin for 7 days. Furthermore, more azithromycin than tobramycin patients presented an early clinical cure at Day 3. Due to its twice daily dosing regimen for 3 days, azithromycin represents a step forward in the management of purulent bacterial conjunctivitis, especially in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.